7,500 pharmaceutical scientists to explore therapies for new millennium

June 18, 2000

AAPS Annual Meeting Takes Place in Indianapolis, Oct. 29 - Nov. 2 ARLINGTON, Va. -- More than 7,500 pharmaceutical scientists will gather in Indianapolis, October 29 - November 2 at the 2000 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition to explore Unmet Medical Needs: Therapies for the New Millennium. Scientists from around the world will learn, network and explore new scientific research and technologies.

"The AAPS Annual Meeting is the largest gathering of pharmaceutical scientists worldwide," said AAPS President Richard Bergstrom, Ph.D. "Scientists at this meeting will present close to 2,000 contributed papers featuring important scientific findings."

The plenary session, "Unmet Medical Needs: Therapies for the New Millennium," takes place on Oct. 30, 8:30 a.m. - 12:00 p.m. The session will reflect on outstanding achievements in the pharmaceutical sciences during the 20th Century and the future of drug discovery, drug development, clinical research and new technologies in the new millennium. Plenary topics and speakers are:"The plenary session features leading experts in the pharmaceutical sciences discussing unmet needs in the various therapeutic areas they represent," said AAPS Annual Meeting Program Chair Diane Burgess, Ph.D. "The session will highlight the unmet medical needs for several non-communicable and communicable disease states including diabetes, cancer, CNS disorders, and AIDS, along with the impact of the pharmaceutical sciences on the discovery, delivery, and development of new therapies."

The meeting will offer more than 70 educational sessions including symposia, short courses, and roundtable discussions. Topics to be presented include:An open forum, entitled "Exposure-Response: How and When Will It Affect Drug Development and Regulatory Decision Making," will take place November 2, 1:30 p.m.

- 5:00 p.m. In this session, participants will discuss the strengths and limitations of pharmacokinetics (PK)/pharmacodynamics (PD) in drug development and regulatory decision making, and ways to advance the value of PK/PD in the future. The forum will provide feedback on key principles of "best practices" that should be considered for inclusion in the Food and Drug Administration's (FDA) draft PK/PD guidance.

More than 450 companies will exhibit at this year's Exposition, October 30 - November 1 at the Indiana Convention Center in Indianapolis. Exhibiting companies are involved in areas such as contract research and analytical services, contract manufacturing, drug delivery systems, drug development, and laboratory instruments and equipment.
-end-
For detailed information about the meeting and overviews of the presentations, visit AAPS Online at http://www.aaps.org/annualmeet/2000.html . For press registration information, contact Debbie Werfel at 703-248-4743 or werfel@aaps.org .

Editor's Note: In early September, abstracts of the papers to be presented at the meeting will be published in AAPS PharmSciSM at http://www.pharmsci.org .

AAPS PharmSciSM is an exclusively online journal of AAPS. AAPS PharmSci offers a forum for the rapid exchange and dissemination of scientific knowledge in the pharmaceutical sciences.

AAPS is a professional, scientific society of more than 10,000 members employed in academia, industry, government and other research institutes worldwide. Founded in 1986, AAPS aims to advance science through the open exchange of scientific knowledge, serve as an information resource, and contribute to human health through pharmaceutical research and development. For more information about AAPS, visit AAPS Online at http://www.aaps.org .

American Association of Pharmaceutical Scientists

Related Drug Development Articles from Brightsurf:

FDA support for oncology drug development during COVID-19
This Viewpoint from the U.S. Food and Drug Administration puts into context recent guidance on clinical trials during COVID-19 for oncology and shares insight regarding regulatory challenges and lessons learned.

COVID-19 drug development could benefit from approach used against flu
A new study from researchers at The University of Texas at Austin has found that some antivirals are useful for more than helping sick people get better -- they also can prevent thousands of deaths and hundreds of thousands of virus cases if used in the early stages of infection.

Chemistry breakthrough could speed up drug development
Scientists have successfully developed a new technique to reliably grow crystals of organic soluble molecules from nanoscale droplets, unlocking the potential of accelerated new drug development.

New model of the GI tract could speed drug development
MIT engineers have devised a way to speed new drug development by rapidly testing how well they are absorbed in the small intestine.

Super-charging drug development for COVID-19
Researchers are using cell-free manufacturing to ramp up production of valinomycin, a promising drug that has proven effective in obliterating SARS-CoV in cellular cultures.

Drug development for rare diseases affecting children is increasing
The number of treatments for rare diseases affecting children has increased, a new study suggests.

New opportunity for cancer drug development
After years of research on cell surface receptors called Frizzleds, researchers at Karolinska Institutet in Sweden provide the proof-of-principle that these receptors are druggable by small molecules.

Novel paradigm in drug development
Targeted protein degradation (TPD) is a new paradigm in drug discovery that could lead to the development of new medicines to treat diseases such as cancer more effectively.

Turbo chip for drug development
In spite of increasing demand, the number of newly developed drugs decreased continuously in the past decades.

A breakthrough for brain tumor drug development
Glioblastoma is a devastating disease with poor survival stats due in part to a lack of preclinical models for new drug testing.

Read More: Drug Development News and Drug Development Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.